Skip to main content
Premium Trial:

Request an Annual Quote

Forensic Genomics Firm Othram Raises $18M in Series B Round

NEW YORK — Forensic genomics company Othram said last week that it has raised $18 million in a Series B financing round led by Gigafund.

Othram combines DNA sequencing from degraded or low-input source material with advanced human identification applications. It has been working with academic researchers, forensic scientists, medical examiners, and law enforcement agencies on unsolved crimes. The Woodlands, Texas-based company said it will use the new funding to continue development of its genetic testing technology and expand its operations throughout North America.

"The family and friends of victims will not be around forever, and once they are gone then the opportunity to do right by them is lost," Othram CEO David Mittelman said in a statement. "We have technology that can bring answers and we need to make this technology available for all cases."

In 2019, Othram raised $4 million in Series A funding and was awarded a $10,000 research sequencing grant from Illumina Accelerator.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.